Currently, out of the existing stock ratings of Stan Berenshteyn - 19 which are a Buy (55.88%), 13 which are a Hold (38.24%), 2 which are a Sell (5.88%)

Stan Berenshteyn

Work Performance Price Targets & Ratings Chart

Analyst Stan Berenshteyn works at WELLS FARGO and is covering the Healthcare sector with 65 price targets and ratings displayed on 7 stocks.

Stan Berenshteyn's average stock forecast success ratio is 52.55% with an average time for price targets to be met of 72.14 days.

Most recent stock forecast was given on DOCS, at 11-Aug-2023.

Wall Street Analyst Stan Berenshteyn

Analyst best performing recommendations are on ACCD (ACCOLADE).
The best stock recommendation documented was for GDRX (GOODRX HOLDINGS) at 8/10/2023. The price target of $7 was fulfilled within 7 days with a profit of $1.25 (15.15%) receiving and performance score of 21.65.

Average potential price target upside

OMCL Omnicell ACCD Accolade GDRX GoodRx Holdings HQY HealthEquity DOCS HCAT Health Catalyst TDOC Teladoc Health

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

75

$21.16 (39.30%)

80

1 months 17 days ago

4/8 (50%)

$22.44 (26.80%)

123

Buy

88

$34.16 (63.45%)

88

1 months 19 days ago

7/12 (58.33%)

$27.62 (33.54%)

109

Buy

70

$16.16 (30.01%)

66

1 months 19 days ago

7/13 (53.85%)

$17.75 (16.59%)

282

Buy

56

$2.16 (4.01%)

65

2 months 1 days ago

3/7 (42.86%)

$24.1 (21.93%)

110

Hold

57

$3.16 (5.87%)

146

10 months 3 days ago

2/2 (100%)

$5.68 (6.66%)

34

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Stan Berenshteyn is most bullish on?

Potential upside of $5.39 has been obtained for HCAT (HEALTH CATALYST)

Which stock is Stan Berenshteyn is most reserved on?

Potential downside of $1.24 has been obtained for GDRX (GOODRX HOLDINGS)

What Year was the first public recommendation made by Stan Berenshteyn?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart